Study of SHOX2 and PTGER4 Methylation Markers for Monitoring Recurrence Risk in Early-Stage Non-Small Cell Lung Cancer Patients Treated with Co-ablation Therapy

What this Trial Is About

Lung cancer, particularly non-small cell lung cancer NSCLC, is one of the most common and deadly cancers worldwide. Surgery is the main curative treatment for early-stage patients however, some patients cannot undergo surgery due to other health issues. For these patients, Co-ablation system therapy offers a minimally invasive treatment option. Despite imaging showing complete tumor removal, minimal residual disease MRD may remain, potentially causing recurrence. This study investigates how methylation markers of the SHOX2 and PTGER4 genes in blood can monitor MRD and evaluate treatment effectiveness after Co-ablation therapy in NSCLC patients. Participants will undergo Co-ablation system therapy followed by blood sample collection at multiple time points before treatment, then at 3 days, and 1, 3, 6, 12, 18, and 24 months after treatment. These samples will be analyzed for methylation levels of the SHOX2 and PTGER4 genes to detect MRD. The study will compare methylation results with imaging and tumor marker tests to assess how well methylation predicts recurrence and therapeutic response. Patients will be grouped into high-risk or low-risk categories based on methylation status. Throughout the study, researchers will track changes in methylation over time and measure outcomes like disease-free survival and recurrence rates. They will also evaluate the time methylation markers predict recurrence compared with traditional methods. Participants will be monitored for up to two years after treatment. The study aims to provide a scientific basis for personalized treatment plans and early detection of lung cancer recurrence.

Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy